<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML><HEAD>
<META http-equiv=Content-Type content="text/html; charset=iso-8859-1">
<META content="MSHTML 6.00.2600.0" name=GENERATOR>
<STYLE></STYLE>
</HEAD>
<BODY bgColor=#ffffff>
<DIV><SPAN
style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial; mso-ansi-language: ES; mso-fareast-language: ES; mso-bidi-language: AR-SA">estimadas
y estimados<BR>un pedido de septiembre de Public Citizen a la FDA se ve
respaldado por un <BR>trabajo en el JAMA<BR><BR>Los autores del trabajo
publicado en JAMA concluyen que comparado con placebo o pioglitazona
muraglitazar se asocio con un exceso de incidencia de la variable principal
combinada de muerte, eventos adversos cardiovasculares mayores(IAM, ACV,
AIT) ye insuficiencia cardiaca congestiva. Basados en variables de laboratorio
este agente no debe ser aprobado para el tratamiento de la diabetes hasta
que se establezca su seguridad en ensayos especialmente diseñados para detectar
eventos cardiovasculares.<BR></SPAN></DIV>
<DIV><SPAN
style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial; mso-ansi-language: ES; mso-fareast-language: ES; mso-bidi-language: AR-SA">el
articulo<BR>Steven E. Nissen; Kathy Wolski; Eric J. Topol Effect of Muraglitazar
on Death and Major Adverse Cardiovascular Events in<BR>Patients With Type 2
Diabetes Mellitus.JAMA 2005;294 2581-2586 esta disponible en:<BR><A
href="http://jama.ama-assn.org/cgi/reprint/294/20/2581">http://jama.ama-assn.org/cgi/reprint/294/20/2581</A><BR><BR>y
un editorial relacionado<BR><BR>James M. Brophy Selling Safety--Lessons From
Muraglitazar JAMA 2005;294 2633-2635<BR>disponible en :
<BR><A
href="http://jama.ama-assn.org/cgi/content/extract/294/20/2633?etoc">http://jama.ama-assn.org/cgi/content/extract/294/20/2633?etoc</A></SPAN></DIV>
<DIV><SPAN
style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial; mso-ansi-language: ES; mso-fareast-language: ES; mso-bidi-language: AR-SA"><FONT
face=Arial></FONT></SPAN> </DIV>
<DIV><SPAN
style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial; mso-ansi-language: ES; mso-fareast-language: ES; mso-bidi-language: AR-SA"></SPAN> </DIV>
<DIV><SPAN
style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial; mso-ansi-language: ES; mso-fareast-language: ES; mso-bidi-language: AR-SA">saludos</SPAN></DIV>
<DIV><SPAN
style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial; mso-ansi-language: ES; mso-fareast-language: ES; mso-bidi-language: AR-SA">Martín
Cañás</SPAN></DIV>
<DIV><SPAN
style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial; mso-ansi-language: ES; mso-fareast-language: ES; mso-bidi-language: AR-SA">La
Plata, Argentina</SPAN></DIV></BODY></HTML>